Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual Therapy-Reference-Cited by-同舟云学术

Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual Therapy

Published:2022-12-01 Issue:4 Volume:91 Page:381-389
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Dragoni Filippo,Rossetti Barbara,Lombardi Francesca,Spertilli Raffaelli Chiara,Bartolini Niccolò,Giammarino Federica,Moschese Davide,Di Giambenedetto Simona,Fabbiani Massimiliano,De Luca Andrea,Vicenti Ilaria,Zazzi Maurizio,Saladini Francesco

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference20 articles.

1. Two drugs regimens for HIV;Waters;Curr Opin Infect Dis.,2020

2. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety;Cento;J Glob Antimicrob Resist.,2020

3. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study;Van Wyk;Clin Infect Dis.,2020

4. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies;Llibre;Lancet,2018

5. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial;Fabbiani;J Antimicrob Chemother.,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA);The Journal of Infectious Diseases;2024-09-03